Publication:
Effects of Recombinant Human Granulocyte Colony-Stimulating Factor (Filgrastim) on ECG Parameters in Neutropenic Patients A Single-Centre, Prospective Study

Simple item page
dc.contributor.authorDENİZBAŞI ALTINOK, ARZU
dc.contributor.authorsGuneysel, Ozlem; Onur, Ozge Ecmel; Denizbasi, Arzu
dc.date.accessioned2022-03-12T17:37:03Z
dc.date.available2022-03-12T17:37:03Z
dc.date.issued2009
dc.description.abstractBackground and objective: Human granulocyte colony-stimulating factor (G-CSF) is a haematopoietic hormone that promotes the growth, proliferation, differentiation and maturation of neutrophil precursors. Filgrastim is a recombinant human G-CSF. Myocardial infarction, atrial fibrillation and arrhythmia have been reported in several patients with malignancy receiving filgrastim, but a causal relationship with the drug has not been established. The purpose of this study was to investigate the changes in ECG parameters in neutropenic patients during treatment with filgrastim. Methods: This was a single-centre, prospective study carried out in a hospital emergency room. Patients with neutropenia and malignancy who were required to receive filgrastim were eligible for the study. After a reference ECG had been obtained, filgrastim was administered to all patients at a dose of 5 mu g/kg/day subcutaneously for 2 days. Follow-up ECGs were then obtained at 12-hourly intervals. Continuous telemetric monitoring was conducted throughout hospitalization. Results: Serial ECG parameters were compared in 102 patients. There were no statistically significant differences between baseline and follow-up ECG measurements of rhythm, P-wave duration, PR interval, QRS-wave duration, corrected QT (QTc) interval, ECG axis, premature supraventricular events, ventricular arrhythmia, R-wave progression, right bundle branch block or left bundle branch block. There was a significant reduction in mean heart rate in subsequent ECGs compared with baseline (p < 0.05). Conclusion: This study did not demonstrate any ECG changes other than a significant reduction in mean heart rate in this selected population of neutropenic patients given 2 days' treatment with subcutaneous 5 mu g/kg/day of filgrastim.
dc.identifier.doi10.2165/00044011-200929080-00005
dc.identifier.issn1173-2563
dc.identifier.pubmed19591516
dc.identifier.urihttps://hdl.handle.net/11424/229339
dc.identifier.wosWOS:000268545100005
dc.language.isoeng
dc.publisherADIS INT LTD
dc.relation.ispartofCLINICAL DRUG INVESTIGATION
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCHEMOTHERAPY
dc.subjectCOMPLICATIONS
dc.subjectCANCER
dc.titleEffects of Recombinant Human Granulocyte Colony-Stimulating Factor (Filgrastim) on ECG Parameters in Neutropenic Patients A Single-Centre, Prospective Study
dc.typearticle
dspace.entity.typePublication
local.avesis.idcec5bf04-13dc-4de4-a915-bf2160b1bd5e
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages5
oaire.citation.endPage555
oaire.citation.issue8
oaire.citation.startPage551
oaire.citation.titleCLINICAL DRUG INVESTIGATION
oaire.citation.volume29
relation.isAuthorOfPublication85d7879a-b827-49ad-8b5f-77e6661077c7
relation.isAuthorOfPublication.latestForDiscovery85d7879a-b827-49ad-8b5f-77e6661077c7

Files

Collections

Research Outputs